Abstract
After treatment of acute Kawasaki disease, 0.2–0.3 % of patients have giant coronary aneurysms (≥8 mm in diameter). These aneurysms are less likely to regress and may result in stenosis leading to coronary thrombosis and myocardial infarction. Although there has been no randomized controlled trial of treatments to prevent thrombosis of giant coronary aneurysms, several case-control studies have compared warfarin plus aspirin with antiplatelet medications given without warfarin. In addition, a recent meta-analysis confirmed the efficacy of warfarin plus aspirin in decreasing the incidence of coronary artery occlusion, myocardial infarction, and cardiac death. Anticoagulant therapy must be carefully monitored because warfarin can cause serious hemorrhagic complications. The efficacy of new drug regimens, including double antiplatelet treatment and factor Xa inhibitors, should be investigated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008). Circ J. 2010;74(9):1989–2020. http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawasy_d.pdf. Accessed August 26, 2014.
Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol. 2012;22(3):216–21. http://dx.doi.org/10.2188/jea.JE20110126 PMID:22447211.
Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975;86(6):892–8. http://dx.doi.org/10.1016/S0022-3476(75)80220-4 PMID:236368.
Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–85. http://dx.doi.org/10.1161/01.CIR.94.6.1379 PMID:8822996.
Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17(5):690–3. http://dx.doi.org/10.1007/s10157-012-0734-z PMID:23188196.
Suda K, Iemura M, Nishiono H, Teramachi Y, Koteda Y, Kishimoto S, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience. Circulation. 2011;123(17):1836–42. http://dx.doi.org/10.1161/CIRCULATIONAHA.110.978213 PMID:21502578.
Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr. 1986;108(6):923–7. http://dx.doi.org/10.1016/S0022-3476(86)80928-3 PMID:3712157.
Kuramochi Y, Ohkubo T, Takechi N, Fukumi D, Uchikoba Y, Ogawa S. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr Int. 2000;42(5):470–5. http://dx.doi.org/10.1046/j.1442-200x.2000.01270.x PMID:11059533.
Ohkubo T, Fukazawa R, Ikegami E, Ogawa S. Reduced shear stress and disturbed flow may lead to coronary aneurysm and thrombus formations. Pediatr Int. 2007;49(1):1–7. http://dx.doi.org/10.1111/j.1442-200X.2007.02312.x PMID:17250496.
Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg. 2012;114(2):275–85. http://dx.doi.org/10.1213/ANE.0b013e31823a088c PMID:22104070.
Murakami T, Tanaka N. The physiological significance of coronary aneurysms in Kawasaki disease. EuroIntervention. 2011;7(8):944–7. http://dx.doi.org/10.4244/EIJV7I8A149 PMID:22157479.
Onouchi Z, Hamaoka K, Sakata K, Ozawa S, Shiraishi I, Itoi T, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of therapeutic regimens. Circ J. 2005;69(3):265–72. http://dx.doi.org/10.1253/circj.69.265 PMID:15731529.
Sugahara Y, Ishii M, Muta H, Iemura M, Matsuishi T, Kato H. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29(2):398–401. http://dx.doi.org/10.1007/s00246-007-9132-9 PMID:18027010.
Suda K, Kudo Y, Higaki T, Nomura Y, Miura M, Matsumura M, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J. 2009;73(7):1319–23. http://dx.doi.org/10.1253/circj.CJ-08-0931 PMID:19436123.
Levy DM, Silverman ED, Massicotte MP, McCrindle BW, Yeung RS. Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. J Rheumatol. 2005;32(5):928–34. PMID:15868632.
Su D, Wang K, Qin S, Pang Y. Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease: a meta-analysis [Epub ahead of print]. Cardiology. 2014;129(1):55–64. http://dx.doi.org/10.1159/000363732 PMID:25116427.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. American academy of pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–71. http://dx.doi.org/10.1161/01.CIR.0000145143.19711.78 PMID:15505111.
Sengupta D, Kahn AM, Kung E, Esmaily Moghadam M, Shirinsky O, Lyskina GA, et al. Thrombotic risk stratification using computational modeling in patients with coronary artery aneurysms following Kawasaki disease [Epub ahead of print]. Biomech Model Mechanobiol. 2014;13(6):1261–76. http://dx.doi.org/10.1007/s10237-014-0570-z PMID:24722951.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. http://dx.doi.org/10.1056/NEJMoa1107039 PMID:21870978.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan
About this chapter
Cite this chapter
Suda, K. (2017). Antiplatelet and Antithrombotic Therapy for Giant Coronary Aneurysm. In: Saji, B., Newburger, J., Burns, J., Takahashi, M. (eds) Kawasaki Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56039-5_22
Download citation
DOI: https://doi.org/10.1007/978-4-431-56039-5_22
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56037-1
Online ISBN: 978-4-431-56039-5
eBook Packages: MedicineMedicine (R0)